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Myosin Heavy ChainThe term hereditary inclusion-body myopathies (HIBMs) deﬁnes a group of rare muscle disorders with autoso-
mal recessive or dominant inheritance and presence of muscle ﬁbers with rimmed vacuoles and collection of cy-
toplasmic or nuclear 15–21 nm diameter tubuloﬁlaments as revealed bymuscle biopsy. The most common form
of HIBM is due to mutations of the GNE gene that codes for a rate-limiting enzyme in the sialic acid biosynthetic
pathway. This results in abnormal sialylation of glycoproteins that possibly leads to muscle ﬁber degeneration.
Mutations of the valosin containing protein are instead responsible for hereditary inclusion-body myopathy
with Paget's disease of the bone and frontotemporal dementia (IBMPFD), with these three phenotypic features
having a variable penetrance. IBMPFD probably represents a disorder of abnormal cellular trafﬁcking of proteins
andmaturation of the autophagosome. HIBMwith congenital joint contractures and external ophthalmoplegia is
due to mutations of the Myosin Heavy Chain IIa gene that exerts a pathogenic effect through interference with
ﬁlament assembly or functional defects in ATPase activity. This review illustrates the clinical and pathologic
characteristics of HIBMs and the main clues available to date concerning the possible pathogenic mechanisms
and therapeutic perspectives of these disorders. This article is part of a Special Issue entitled: Neuromuscular Dis-
eases: Pathology and Molecular Pathogenesis.
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With the term “hereditary inclusion-body myopathies” (HIBMs)
Askanas and Engel ﬁrstly deﬁned in 1993 a group of clinically heteroge-
neous and generally progressive muscle disorders with autosomal
recessive or dominant inheritance. Despite different etiologies and clin-
ical presentations, all of them are characterized by muscle pathology
similar to that of sporadic inclusion-body myositis (s-IBM), the most
common acquiredmyopathy in elderly patients, except for the presence
of lymphocytic inﬂammation [1]. Indeed, typical abnormalities of
HIBMs as revealed by muscle biopsy include the presence of
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lini), mirabella@rm.unicatt.itand centralization of myonuclei, ii) muscle ﬁbers containing various-
sized andmainly rimmedvacuoles and iii) cytoplasmic and occasionally
nuclear 15 to 21 nm diameter tubuloﬁlaments by electron microscopy
investigation [2]. This review will illustrate the clinical and pathologic
characteristics of the most common forms of HIBM and the main clues
available to date concerning their possible pathogenic mechanisms
and therapeutic perspectives.
2. GNE myopathy
The most common form of HIBM was originally described in
Middle Eastern patients [3] and is tied to mutations of the UDP-N-
acetylglucosamine 2-epimerase/N-acetylmannosamine kinase (GNE,
MIM# 603824) gene, hence the name GNE myopathy (MIM# 600737)
[4]. GNE codes for a bifunctional enzyme (GNE/MNK), with both epimer-
ase and kinase activities that has a central role in the sialic acid biosyn-
thetic pathway [5]. A homozygous mutation converting methionine to
threonine at codon 712 (p.M712T) has been found in all Middle Eastern
patients, thus suggesting a common founder effect [4,6,7]. GNE muta-
tions have been also found in patients with Nonaka myopathy or distal
myopathy with rimmed vacuoles (DMRV; MIM# 605820) [8], therefore
conﬁrming that GNEmyopathy and DMRV are the same entity. A strong
linkage disequilibrium is present also in Japanese GNE myopathy
patients as the vast majority of them harbor the homozygous missense
mutation p.V572L [9]. On the contrary, patients of other ethnic origin
are usually compound heterozygous for mutations in different regions
of the gene [4,7,10].
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The onset of GNE myopathy is usually in late teenage or early adult-
hood years, with weakness and atrophy of the distal muscles of the
lower extremities and later proximal progression involving the
iliopsoas, gluteal, hamstring and adductor muscles. The quadriceps
muscles often retain a normal or close-to-normal strength despite the
severe involvement of other hipmuscles and upper limbmuscles usual-
ly become affected later in the disease. Serum creatine kinase (CK) level
is normal or slightly elevated and electromyography (EMG) may show
thepresence ofmixedmyopathic and neurogenic features [3]. However,
following the identiﬁcation of the causative gene defect, patients with
GNE myopathy characterized by an unusual clinical or pathologic phe-
notype have been progressivelymore recognized [6,9,11]. As a corollary,
it has been also found that the sparing of the quadriceps is a typical but
not exclusive feature of GNE myopathy, as it can be present also in pa-
tients with a muscle disorder unrelated to the GNE gene [12]. Indepen-
dently from the typicalness of the clinical phenotype, even from the
early stages of the disease muscle MRI usually shows a constant and se-
vere fatty–ﬁbrous replacement of the biceps femoris short headmuscle,
always accompanied by less severe affection of the gluteus minimus,
tibialis anterior, extensor hallucis and digitorum longus, soleus and gas-
trocnemius medialis. This unique combination of muscle involvement
constitutes an “MRI signature” of GNE myopathy in its initial stages
and we believe it may be of diagnostic value [13].
Age of onset and degree of progression of symptomsmay be variable
and this raises the possibility that different GNE mutations are not
functionally equivalent. Although extensive genotype–phenotype cor-
relation studies are lacking, in a Japanese cohort of GNE myopathy pa-
tients it has been shown that the homozygous state for the p.V572L
mutation results in more severe phenotypes with earlier onset and
faster progression of the disease. On the contrary, the secondmost com-
monmutation in this population, the p.A172V, seems to be amildermu-
tation, as heterozygous patients carrying this mutation along with the
p.V572L usually showa later onset of symptoms [14]. Of course, the pos-
sibility exists that also other yet unknown factors may modulate the
clinical phenotype. Moreover, the selective involvement of skeletal
muscle is overtly peculiar as this tissue expresses relatively low levels
of the enzyme in comparison to other tissues (i.e. liver, lung and kidney)
that remain unaffected. This suggests the existence of putative suscepti-
bility factors of skeletal muscle to a generalized metabolic impairment.
Muscle pathology of GNEmyopathy is similar to that of s-IBM, the
most frequent muscle disorder occurring in elderly patients. In fact,
in both disorders there is the abnormal accumulation of proteins
commonly associated with Alzheimer's disease brain pathology in-
cluding Amyloid β (Aβ) and paired helical ﬁlaments containing
hyperphosphorylated tau [2] (Fig. 1). The similarities between GNEmy-
opathy and s-IBM muscles suggest that, despite different etiologies,
both disorders possibly share some common downstream pathogenic
mechanisms.
2.2. Possible pathogenic mechanism
The molecular pathogenic mechanism/s of GNE myopathy are for
the most part undeﬁned. Being GNE/MNK a rate limiting enzyme in
the sialic acid biosynthetic pathway it is conceivable that an impairment
of sialic acid metabolism may play a role in the pathogenic cascade. Si-
alic acid is normally present on the distal ends of N- and O-glycans
and is involved inmany biological functions including cellular adhesion,
formation or masking of recognition determinants, stabilization of
glycoprotein structure and signal transduction [5]. Transgenic mice ex-
pressing the human GNE gene with the p.D176V mutation on a Gne
knockout background (Gne(−/−)hGNED176V-Tg) have reduced sialic
acid in serum and other tissues and develop a myopathy with a similar
molecular phenotype. Indeed, the muscle of these mice shows rimmed
vacuoles and cytoplasmic inclusions within the ﬁbers. Interestingly,abnormal muscle ﬁbers of Gne(−/−)hGNED176V-Tg mice accumulate
Aβ and this seems to precede other abnormalities [15].
Various muscle glycoproteins have been found to be hyposialylated
in GNE myopathy muscle although their relative importance in leading
to disease phenotype remains to be fully elucidated. For example, α-
dystroglycan, a structural protein that provides connection between
the cytoskeleton and proteins of the extracellularmatrix can be variably
hyposialylated but its laminin binding capacity is never impaired, thus
undermining a possible role of the protein in the pathogenesis of this
disorder [16]. The neural cell adhesion molecule (NCAM), a member
of the immunoglobulin superfamily of adhesion molecules that
bind long linear homopolymers of sialic acid, is for the most part
hyposialylated in the muscle and serum of GNE myopathy patients as
evidenced by different experimental techniques [12,17]. Although
also in this case a possible pathogenic role of hyposialylated NCAM in
GNE myopathy is not known, such peculiar feature can be used as a
pre-genetic biochemical marker in the routine diagnostic workup
if GNE myopathy is suspected. This may be of particular value when
the clinician is challenged by uncommon clinical or pathologic features
[11].
Very recently, in a cellular model of the disease it has been shown
that GNE impairment is associated with abnormal sialylation of the
cell membrane receptor β1 integrin, a protein involved in cell adhesion.
Hyposialylated β1 integrin remains localized to internal vesicles but
upon ligand stimulation it migrates to the plasma membrane where it
bindsmore avidly to ﬁbronectin. It is possible that the increased cell ad-
hesion leads to disruption of muscle function by affecting the cytoskel-
etal network through the activation of speciﬁc signaling pathways [18].
Whether such mechanism indeed takes place in the diseased muscle of
GNE myopathy remains to be demonstrated.
Aβ accumulates within abnormal ﬁbers of GNE myopathy muscle
and possibly plays a central role in the pathogenic cascade through its
cytotoxic effect, as previously shown for s-IBM [19]. Indeed, in the
mouse model of the disease, the accumulation of Aβ is an early event
in the pathogenic cascade as it precedes the appearance of other abnor-
malities such as rimmed vacuoles [15]. Although the functional relation-
ship between abnormal sialic acid metabolism and the accumulation of
Aβ is still unclear, several lines of evidence suggest an impairment of
cellularmechanisms involved in Aβ processing. For example, Neprilysin
(NEP), a sialoglycoprotein known to cleave Aβ at multiple sites, is
hyposialylated in GNE myopathy muscle and this is associated with a
signiﬁcant reduction of its expression and enzymatic activity [20]. The
link between abnormal sialylation and functional impairment of NEP
is provided by the evidence that, in vitro, the enzymatic removal of sialic
acid from glycoproteins of cultured human normal myotubes results in
reduced NEP activity and this is associated with the appearance of Aβ
cytoplasmic inclusions [20]. Similarly, NEP activity is reduced also in
the muscle of Gne(−/−)hGNED176V-Tg mice and can be recovered to
values comparable to control littermates upon treatmentwith synthetic
sugar compounds that increase the sialylation level of glycoproteins.
This goes alongwith the reduction of the burden of Aβwithinmuscle ﬁ-
bers [21]. Taken together, these data imply that NEP may be the major
enzyme involved in the cellular Aβ clearing system that is affected by
hyposialylation. How hyposialylation of NEP affects its stability is not
known, although interferencewith the correct processing of the protein
in the endoplasmic reticulum (ER) leading to increased degradation can
be hypothesized. In general terms, hyposialylation of glycoproteinsmay
perturb their proper folding and trafﬁcking through the ER and Golgi
network and the translocation to the plasma membrane. This would
activate a mechanism of ER stress that is intended to manage the
accumulation of abnormal proteins. Once an ER stress condition is
established, the misfolded and unfolded proteins trapped in the ER are
retrotranslocated to the cytoplasm and degraded by either the ubiqui-
tin–proteasome system or through the autophagic process [22]. Indeed,
there is evidence that ER stress and the unfolded protein response, two
cellular mechanisms intended to cope with abnormal folding and
Fig. 1. Confocal microscopy images of triple immunoﬂuorescence staining of muscle biopsies of GNE myopathy and IBMPFD patients. Either SMI31 or p62 antibodies are labeled by
Alexaﬂuor 594 (red); falloidin-FITC binding tomuscle actin (green) and nuclear staining Hoechst (blue) are used to counterstainmuscle ﬁbers.Upper panel: In GNEmyopathy, vacuolated
muscle ﬁbers show a strong immunoreactivity with SMI31 and p62 antibodies in more roundish “plaque-like” cytoplasmic inclusions. Lower panel: in IBMPFD, vacuolated muscle ﬁbers
contain multiple immunoreactive foci labeled by SMI31 and p62 mainly in the form of squiggly “tangle-like” inclusions. Scale bar represents 10 μm.
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(Broccolini and Mirabella, personal observation 2010, and [23]).
A schematic representation of the pathogenicmechanism/s underly-
ing GNE myopathy is reported in Fig. 2.
2.3. Therapeutic perspectives
If indeed hyposialylation of glycoproteins plays a pivotal role in the
relentless muscle degeneration observed in GNE myopathy, it is con-
ceivable that restoring a normal sialylation status by exogenous supple-
mentation of sialic acid, or of one of its metabolic precursors, may help
to recover homeostasis of muscle ﬁbers. The ﬁrst short-term open-
label pilot study of administration of sialic acid has been performed on
4 GNE myopathy patients who received sialic acid via intravenous im-
mune globulin G, a glycoprotein that contains 8 μmol of this sugar per
gram, for onemonth. The systemic supplementation of sialic acid result-
ed in a temporary improvement of objective and subjectivemeasures of
muscle strength and function at the end of the treatment, although thiswas not associated with increased sialylation of speciﬁc muscle glyco-
proteins [24]. With all the limitations implicit with a small and short-
term study, the authors reasoned that the provision of sialic acid may
hold a therapeutic promise. Previous studies have suggested that the
use of N-acetyl-D-mannosamine (ManNAc) represents a suitable alter-
native to sialic acid in exogenous supplementation therapy, as it enters
the sialic acid biosynthetic pathway immediately downstream themet-
abolic block determined by mutated GNE/MNK and is phosphorylated
by a different enzyme with ManNAc kinase activity [25]. Indeed,
Malicdan et al. have demonstrated that the oral prophylactic supple-
mentation of ManNAc in Gne(−/−)hGNED176V-Tgmice results in an in-
crease of sialic acid in muscle to a nearly normal level and prevents the
development of the muscle phenotype. In particular, ManNAc-treated
mice have increased strength, muscle mass, body weight and overall
survival compared to untreated control littermates. This is associated
with an increase of themeanmuscle ﬁber cross-sectional area and a re-
duction of vacuolated ﬁbers containing Aβ inclusions [26]. A phase I
clinical trial of sialic acid supplementation therapy for human patients
Fig. 2. Schematic representation of the pathogenic mechanism/s underlying GNE myopathy.
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September 2011–April 2012 in the US, the latter using slow release tab-
lets of sialic acid, and a phase II trialwill be conducted in the near future.
3. Hereditary inclusion-body myopathy with Paget's disease of the
bone and frontotemporal dementia
Hereditary inclusion-bodymyopathy associatedwith Paget's disease
of bone (PDB) and frontotemporal dementia (IBMPFD, MIM# 167320)
is a rare multisystem degenerative autosomal dominant disorder due
to mutations of the valosin-containing protein gene (VCP, MIM#
601023) [27]. The threemain clinical features of IBMPFDhave a variable
penetrance. Indeed, while 90% of patients develop muscle weakness
(the presenting symptom in more than half of patients), approximately
50% show osteolytic bone lesions consistent with PDB and only one
third develop frontotemporal dementia (FTD). Moreover, approximate-
ly 30% of IBMPFD patients may present only a myopathy, thus underly-
ing the importance of inquiring for the presence of dementia or PDB in
othermembers of the family in the early clinical assessment of a patient.
Other phenotypic features have been reported aswell, including dilated
cardiomyopathy, hepatic steatosis, cataracts, sensorymotor axonal neu-
ropathy, pyramidal tract dysfunction, sphincter disturbance, sensori-
neural hearing loss, and amyotrophic lateral sclerosis-like features [28].
3.1. Clinical and pathologic features
Muscle involvement is usually variable, although themajority of pa-
tients display a limb-girdle distribution of weakness and scapular
winging. Axial weakness with head drop and weakness of the distal
limb muscles have also been described [29]. Serum CK level is usually
normal or slightly elevated. EMG reveals myopathic changes often
associated with ﬁbrillation potentials and positive sharp waves [29].
Muscle biopsy features includemyopathic changes with increased scat-
ter of ﬁber diameter, ﬁbers with cytoplasmic rimmed vacuoles and
patchy increase of endomysial connective tissues. Spread out small
angulated ﬁbers are also observed. Immunohistochemistry for Aβ,
ubiquitin and VCP highlights focal cytoplasmic accumulation of these
proteins in the majority of cases [30]. In our experience, antibodies
against polyubiquitinated sequestosome (anti-p62) [31] and anti-
phosphoneuroﬁlaments recognizing phosphorylated tau (SMI31) [32]are also strongly immunoreactive in the majority of vacuolated muscle
ﬁbers, although in a different fashion compared to what is observed in
GNE myopathy (Fig. 1). Of note, accumulation of VCP is not speciﬁc of
IBMPFD as it has been also demonstrated in other muscle disorders
with prominent multi-protein aggregate pathology [33]. Electron
microscopy analysis of skeletal muscle shows tubuloﬁlamentous
inclusions within myoﬁbers and myonuclei (more frequently than in
GNE myopathy) along with disrupted myoﬁbrils, vacuolization and
myelin-like whorls [30].
The features of cognitive decay may be variable among different
patients with IBMPFD. However, in many cases, an early symptom is
language impairmentwith preserved episodicmemory. Later in the dis-
ease, auditory comprehension deﬁcits for one-step commands, alexia,
and agraphiamay be documented. Not uncommonly a behavioral disor-
der or psychotic features are described as initial symptoms. Brain MRI
mainly shows atrophy of the frontal and temporal lobes with ventricu-
lar enlargement. FTD usually lacks the typical pathology of Alzheimer's
disease brain [28]. Differently from other familial variants of FTD due
to mutation of tau protein, a key feature of VCP-related frontotemporal
dementia is the presence of ubiquitinated inclusions within neuronal
nuclei, thus deﬁning IBMPFD as a subtype of frontotemporal degenera-
tion with ubiquitinated inclusions [34,35]. Ubiquitin positive inclusions
co-localize with Trans-activation Response DNA-binding Protein-43
(TDP-43), an RNA binding protein involved in exon skipping of the
pre-mRNA [36]. Interestingly, TDP-43 also accumulates in abnormal
muscle ﬁbers of IBMPFD. However, differently from the brain that pre-
sents only intranuclear ubiquitinated and TDP-43 inclusions, affected
muscle shows both myonuclear and sarcoplasmic inclusions, with
TDP-43 being diminished in the nuclei of inclusion-bearing ﬁbers [37].
TDP-43 redistribution from nucleus to the cytosol is not exclusive of
this disorder as it is observed in other neurodegenerative diseases and
in muscle disorders with rimmed vacuoles such as s-IBM and GNE
myopathy [36,38].
3.2. Possible pathogenic mechanism
VCP, also known as p97, a member of the ATPase associated with di-
verse cellular activities (AAA-ATPase) superfamily, is characterized by a
tripartite structure with an N-terminal domain, involved in ubiquitin
binding, and two central domains, D1 and D2, that bind and hydrolyze
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ubiquitin-dependent protein quality control and intracellular signaling
pathways and participates in ubiquitin-labeled protein processing for
recycling or degradation by the proteasome [40]. It also helps degrade
certain cytosolic proteins and handles protein aggregates. In addition,
VCP contributes to the elimination of regulatory proteins in various in-
tracellular signaling pathways, including those that govern chromatin
remodeling, DNA replication and repair, cell cycle control and apoptosis.
Other known functions comprise membrane fusion, transcription acti-
vation, nuclear envelope reconstruction, and post-mitotic organelle re-
assembly [40–44]. Approximately 20 different missense mutations
have been identiﬁed in patients with IBMPFD, the majority of these in-
volving the N-terminal domain of the protein [45,46]. Interestingly,
codon 155 has been identiﬁed as amutation hot spot, as at least 5 differ-
entmutations involve this codon andan identicalmutation has beende-
scribed in patients with an apparently different genetic background
[46]. It is still unclear how IBMPFD-associated mutations affect the mo-
lecular mechanism/s underlying the protein function. However, recent
studies have suggested that inmutant VCP the D1 domain of the protein
shows abnormal binding to ADP and overall elevated ATPase activity,
thus impacting its capability to process substrate [47].
Increasing evidence point out to an impaired protein processing and
turnover having a role in the pathogenic mechanism of IBMPFD [28,46].
Because VCP participates in protein degradation and autophagy, muta-
tions hampering the protein function result in abnormal accumulation
of ubiquitinated proteins and activation of ER stress response. Indeed,
in vitro, the expression of IBMPFD VCPmutations results in an increase
of ER-associated and cytosolic ubiquitinated inclusions [48]. Moreover,
co-expression of the aggregate-prone expanded polyglutamine in
IBMPFD mutant cells leads to increased aggregated protein compared
to cells expressing the wild type VCP. Overall, it appears that VCP has a
role in autophagosome maturation, as in vitro it has been shown that
these subcellular structures are formed but then fail to mature and be
degraded [48]. Interestingly, TDP-43 accumulates in the cytosol upon
autophagy inhibition, similar to what is seen after IBMPFD mutation
expression, highlighting the possible role of impaired autophagy in
the pathologic changes seen in IBMPFD muscle [48].
A schematic representation of the pathogenicmechanism/s underly-
ing IBMPFD is reported in Fig. 3.
3.3. Therapeutic perspectives
To date there are no promising therapeutic strategies or compounds
for IBMPFD. One can speculate that being IBMPFD a disorder whereFig. 3. Schematic representation of the pathoabnormal trafﬁcking of misfolded and aggregated proteins leads to im-
paired autophagy, then molecules that promote a more efﬁcient trans-
fer of protein aggregates into cellular targets where autophagy takes
place may hold a therapeutic promise. For example, it has been
shown that the expression of the histone deacetylase-6 (HDAC6),
a ubiquitin-binding deacetylase participating to autophagosome–
lysosome fusion and substrate degradation, is able to improves
aggresome formation and protects IBMPFD mutant cells from
polyglutamine-induced cell death [49,50]. In addition, very recently a
very detailed experimental study has shown that a 6-week low-
intensity uphill treadmill exercise regimen can improve the whole-
body strength, and mitochondrial oxidative capacity of the quadriceps
muscles of a IBMPFD mouse model [51]. However, further studies are
required to clarifywhether this experimental evidence can be beneﬁcial
in designing a future avenue of treatment of this disorder.
4. Hereditary inclusion-body myopathy with congenital joint
contractures and external ophthalmoplegia
This form of autosomal dominant HIBM has been ﬁrstly described in
a large multigeneration family from Sweden (MIM# 605637) [52]. Typ-
ical clinical features consists in early joint contractures, external
ophthalmoplegia and predominantly proximal muscle weakness. Joint
contractures normalize during early childhood and overall the myopa-
thy has a mild course in young individuals. A mild upgaze paresis can
be seen. Accordingly, when a muscle biopsy is performed during this
stage, histopathologic abnormalities are usually minor. During adult-
hood the disease has amore aggressive course with weakness and atro-
phy mainly affecting the proximal muscles of the upper and lower
extremities. The quadriceps are usually severely affected. Complete ex-
ternal ophthalmoplegia is a consistent ﬁnding and a hand tremor is
common. Serum CK level can be elevated to up to tenfold the normal
value and EMG shows myopathic changes. Muscle biopsy shows
more pronounced abnormalities consisting in dystrophic changes and
presence of rimmed vacuoles. Structural alterations initially affectmain-
ly type 2A ﬁbers, where electron microscopy investigation reveals focal
disorganization of contractile ﬁlaments, although in older patients all
ﬁber types have morphological changes including rimmed vacuoles
and 15–21 nm tubuloﬁlamentous inclusions [52,53].
This disorder is associated with a mutation of the Myosin Heavy
Chain IIa gene (MyHC-IIa, MIM# 160740) on chromosome 17,
converting glutamic acid to lysine at codon 706 (p.E706K). This affects
the SH1 helix of the protein, the core of myosin head, and therefore
causes a dominant negative effect through interference with ﬁlamentgenic mechanism/s underlying IBMPFD.
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ATPase activity. Because type IIa MyHC is the main constituent of type
2A ﬁbers, this probably justiﬁes the fact that these ﬁbers are predomi-
nantly affected [53].
5. Other variants of hereditary inclusion-body myopathy
Various and less common forms of hereditarymyopathies have been
originally included among the HIBM group based on muscle biopsy
ﬁndings. For example, the autosomal dominant myopathy identiﬁed
as HIBM1 (MIM# 601419) is an adult onset disorder affecting the distal
muscle of the lower extremities and the quadriceps. The identiﬁcation
of mutations of desmin (MIM# 125660) as the causative gene defect
has moved this disorder into the group of myoﬁbrillar myopathies
[54]. Likewise, the hereditary myopathy with early respiratory failure
(MIM# 607569), also initially considered a form of HIBM, is an autoso-
mal dominant disorder that has been later shown to be a titinopathy
[55]. Various reports have described forms of myopathies in isolated
families worldwide with pathologic abnormalities resembling that of
HIBM but clinical characterization and molecular studies are still insuf-
ﬁcient to warrant a precise nosological classiﬁcation.
6. Conclusions
The group of HIBMs embraces rare and different progressive affec-
tions of skeletal muscle having in common peculiar pathologic features
as revealed by muscle biopsy. Despite some similarities, they have
different etiologies and clinical presentations. A considerable amount
of work is now available for the two most common forms of HIBM,
GNE myopathy and IBMPFD, based on both molecular observations on
diseased tissues and establishment of experimental models. This has
helped shed some light on the corresponding pathogenic mechanisms
that are cardinal for future hypothesis of treatment. Instead, much re-
mains to be learned about the other and less common forms of HIBMs
beyond the deﬁnition of the corresponding causative gene defect that,
in the majority of cases, is only beginning to outline a nosological
order in this still magmatic group of muscle disorders.
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